Search results (1320)
« Back to PublicationsPerivascular niche cells sense thrombocytopenia and activate hematopoietic stem cells in an IL-1 dependent manner
Luis TC. et al, (2023), Nature Communications, 14
Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.
McLornan DP. et al, (2023), Br J Haematol
Erythroid differentiation enhances RNA mis-splicing in SF3B1-mutant myelodysplastic syndromes with ring sideroblasts.
Moura PL. et al, (2023), Cancer research
A protocol for simultaneous high-sensitivity genotyping and chromatin accessibility profiling in single cells.
Turkalj S. et al, (2023), STAR Protoc, 4
RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort.
O'Sullivan JM. et al, (2023), Leukemia
Perivascular niche cells sense thrombocytopenia and activate hematopoietic stem cells in an IL-1 dependent manner.
Luis TC. et al, (2023), Nat Commun, 14
Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution.
Rodriguez-Meira A. et al, (2023), Nat Genet
Predicting 10-year breast cancer mortality risk in the general female population in England: a model development and validation study.
Clift AK. et al, (2023), Lancet Digit Health, 5, e571 - e581
UK oncology approvals in 2022: global regulatory collaboration and new regulatory pathways deliver new anti-cancer therapies.
Lythgoe MP. et al, (2023), Lancet Oncol, 24, 963 - 966
Fractionated Versus Single Dose Gemtuzumab Ozogamicin with Determinants of Benefit in Older AML: UK NCRI AML18 Trial.
Freeman SD. et al, (2023), Blood
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Coombes RC. et al, (2023), Nat Commun, 14
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer.
Macaulay VM. et al, (2023), Br J Cancer
Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1.
Sugiyarto G. et al, (2023), J Immunother Cancer, 11
Early phase antitumour clinical trials and palliative medicine.
Virani F. et al, (2023), BMJ Support Palliat Care